Top Markets
#1 ADO Protocol ADO Protocol +337.09%
#2 GoPlus Security GoPlus Security +50.57%
#3 Starpower Starpower +34.89%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.29%
#5 GAIB AID GAIB AID +24.67%
#6 The Black Bull The Black Bull +21.03%
#7 Nockchain Nockchain +18.69%
#8 XMAQUINA XMAQUINA +17.84%
#9 Fake World Assets Fake World Assets +17.04%
#10 DMT-NAT DMT-NAT +14.82%
Coin of the day
ADO Protocol ADO Protocol
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXR
Rang in Aktien #33050
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm... Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Aktienkurs
$0.5625
Marktkapitalisierung
$6.29M
Veränderung (1 Tag)
-25.56%
Veränderung (1 Jahr)
-57.71%
Land
US
Handel Citius Pharmaceuticals, Inc. (CTXR)

Kategorie

Healthcare
Operative Marge für Citius Pharmaceuticals, Inc. (CTXR)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von Citius Pharmaceuticals, Inc. beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von Citius Pharmaceuticals, Inc. von 2026 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
Nicht genügend Daten für die angegebenen Daten.
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.